Kioulafa Magdalini, Kaklamanis Loukas, Mavroudis Dimitris, Georgoulias Vassilis, Lianidou Evi S
Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, 15771, Greece.
Clin Biochem. 2009 Jul;42(10-11):970-5. doi: 10.1016/j.clinbiochem.2009.04.003. Epub 2009 Apr 15.
The aim of our study was to evaluate the prognostic significance of RASSF1A promoter methylation status in operable breast cancer.
By using Methylation Specific PCR, we evaluated the specificity of RASSF1A promoter methylation in 10 breast tumors and matching normal tissues, 10 breast fibroadenomas and 11 normal breast tissues. The prognostic significance of RASSF1A methylation was validated in 93 formalin fixed paraffin-embedded (FFPE) tissues obtained from patients with operable breast cancer.
Methylation of RASSF1A promoter was observed in 1/31 (3.2%) non-cancerous breast tissues and 53/93 (57.0%) early stage breast tumors. The only positive sample in the non-cancerous breast tissues group was found in a histological normal tissue surrounding the tumor. During the follow-up period, 24/93 (25.8%) patients relapsed and 19/93 (20.4%) died. Disease-Free-Interval (DFI) was significantly associated with RASSF1A methylation (p=0.028).
RASSF1A promoter methylation provides important prognostic information in early stage breast cancer patients.
本研究旨在评估RASSF1A启动子甲基化状态在可手术乳腺癌中的预后意义。
通过甲基化特异性PCR，我们评估了10例乳腺肿瘤及配对的正常组织、10例乳腺纤维腺瘤和11例正常乳腺组织中RASSF1A启动子甲基化的特异性。在93例来自可手术乳腺癌患者的福尔马林固定石蜡包埋（FFPE）组织中验证了RASSF1A甲基化的预后意义。
在1/31（3.2%）的非癌性乳腺组织和53/93（57.0%）的早期乳腺肿瘤中观察到RASSF1A启动子甲基化。非癌性乳腺组织组中唯一的阳性样本在肿瘤周围的组织学正常组织中发现。在随访期间，24/93（25.8%）患者复发，19/93（20.4%）患者死亡。无病生存期（DFI）与RASSF1A甲基化显著相关（p = 0.028）。
RASSF1A启动子甲基化为早期乳腺癌患者提供了重要的预后信息。
